Management of Geriatric Bipolar Disorder: A Case Series and Review of Current Evidence-Based Treatment Guidelines

2021 ◽  
Vol 29 (4) ◽  
pp. S17-S18
Author(s):  
David Atkinson ◽  
Rana Jawish
Keyword(s):  
Bipolar Disorder ◽  
Treatment Guidelines ◽  
Case Series ◽  
Current Evidence ◽  
Evidence Based ◽  
Evidence Based Treatment

scholarly journals TRIMETHOPRIM-SULFAMETHOXAZOLE AND SODIUM VALPROATE-INDUCED TOXIC EPIDERMAL NECROLYSIS: A CASE SERIES

2021 ◽  
pp. 3-5
Author(s):  
BHAVANA SRIVASTAVA ◽  
RENU KHANCHANDANI ◽  
VIKRAM SINGH DHAPOLA ◽  
ZAFAR MASOOD ANSARI
Keyword(s):  
Toxic Epidermal Necrolysis ◽  
Sodium Valproate ◽  
Treatment Guidelines ◽  
Case Series ◽  
Evidence Based ◽  
Evidence Based Treatment ◽  
Successful Recovery ◽  
Common Causes ◽  
Potential Risk Factors ◽  
Life Threatening

Toxic epidermal necrolysis (TEN) is a rare and serious but life-threatening dermolytic cutaneous reaction characterized by diffuse and severe exfoliation and destruction of the epidermis of skin and mucosa due to immunological damage of the epidermis which can bring about sepsis and respiratory distress. Drugs are the most common inflicting agents in the generation of TEN. Among drugs, antiepileptics, antipsychotics, and sulfa-drugs are common causes of TEN. Valproate is one of the most common drugs prescribed for epilepsy, was found as causative agent in TEN in very few cases. Among sulfonamides, sulfamethoxazole is commonly used antibiotic which can cause TEN. The evidence-based treatment guidelines are lacking, so the best approach is to recognize and evade potential risk factors and to deliver intensive supportive care immediately to reduce morbidity and mortality. The aim of this case series is to focus on valproate and trimethoprim-sulfamethoxazole (TMP-SMX)-induced TEN, which are commonly used drugs. Here, we present a case series of TEN inflicted by TMP-SMX and sodium valproate in a 23-year-old female and 10-year-old boy, respectively, with successful recovery.

scholarly journals Use of Lugol’s Solution in the Management of Complex Graves’ Disease-a Small Case Series

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A972-A972
Author(s):  
Rufaro Asefa ◽  
Allison Shane Martin
Keyword(s):  
Emergency Department ◽  
Adverse Effects ◽  
Total Thyroidectomy ◽  
Treatment Guidelines ◽  
Case Series ◽  
Graves Disease ◽  
Evidence Based ◽  
Once Daily ◽  
Evidence Based Treatment ◽  
Severe Anxiety

Abstract Background: There are currently no clear guidelines for the peri-operative use of Lugol’s solution (LS) as an alternative to conventional anti-thyroid drug (ATD) therapy in patients with complex Graves’ thyrotoxicosis. Clinical Cases: Case 1 is a 44- year-old woman who presented with symptoms of hyperthyroidism and a moderately enlarged goiter due to Graves disease. She was treated initially with Methimazole 45 mg, once daily which was reduced to 30 mg once daily after a week. She subsequently presented to the emergency department with severe anxiety, sore throat, and a high fever. A blood panel showed evidence of profound agranulocytosis due to Methimazole. Methimazole was stopped and she was treated with a 10-day course of LS followed by a semi-elective total thyroidectomy. Case 2 is a 54-year-old old woman who presented with thyrotoxicosis due to Graves’ disease. She was started on Propylthiouracil (PTU) to which she developed hepatotoxicity and the decision was made to stop PTU. Methimazole was substituted to which she developed a severe desquamating rash hence it had to be stopped immediately. She was given a 10 day course of LS followed by semi-elective total thyroidectomy. Conclusion: In both cases, hyperthyroidism was successfully treated with Lugol’s solution and their surgeries were uneventful with full recovery. Although beneficial, Lugol’s Solution may result in adverse effects such as severe hypothyroidism, escape hyperthyroidism and death. These cases highlight the need for evidence based treatment guidelines for the use of Lugol’s solution in complex hyperthyroid cases.

Acute myocarditis

2014 ◽  
Author(s):  
Demosthenes G. Katritsis ◽  
Bernard J. Gersh ◽  
A. John Camm
Keyword(s):  
Acute Myocarditis ◽  
Current Evidence ◽  
Evidence Based ◽  
Evidence Based Treatment

Classification, diagnosis, and current evidence-based treatment of myocarditis are presented.

scholarly journals Beyond evidence‐based treatment of bipolar disorder: Rational pragmatic approaches to management

2019 ◽  
Vol 21 (7) ◽  
pp. 650-659 ◽  
Author(s):  
Robert M. Post ◽  
Lakshmi N. Yatham ◽  
Eduard Vieta ◽  
Michael Berk ◽  
Andrew A. Nierenberg
Keyword(s):  
Bipolar Disorder ◽  
Evidence Based ◽  
Evidence Based Treatment

Treatment of interictal psychiatric disorder in epilepsy. I. Affective and anxiety disorders

2002 ◽  
Vol 14 (1) ◽  
pp. 39-43 ◽  
Author(s):  
Cm van der Feltz-Cornelis
Keyword(s):  
Anxiety Disorders ◽  
Psychiatric Disorder ◽  
Affective Disorders ◽  
Treatment Guidelines ◽  
Systematic Research ◽  
Evidence Based ◽  
Evidence Based Treatment ◽  
General Psychiatry ◽  
Dsm Iv ◽  
Patients With Epilepsy

Background:Interictal affective disorders are common in patients with epilepsy and there is a need for evidence-based treatment guidelines.Objective:This paper gives an overview of research concerning treatment of interictal affective disorders and interictal anxiety disorders in epilepsy.Methods:Literature review supplemented by clinical experience.Results:Interictal psychiatric disorder can be characterized as intermittent pleomorphic psychopathology. The most common manifestations are interictal dysphoric disorder (IDD) and depression. There is a lack of randomized control trials (RCTs) concerning effectiveness and side-effects of antidepressants in epilepsy patients.Conclusion:Treatment implications of the concept of IDD and other interictal disorders are an optimized dosage of anti-epileptics in combination with antidepressants. This coincides with recent guidelines concerning combinations of psychotropic medication, such as for depression and bipolar disorder, in general psychiatry. Systematic research involving the DSM-IV categories of generalized anxiety disorder, panic disorder and agoraphobia and depression is not yet available. Prevalence and treatment of interictal anxiety disorders and depressive disorder in epilepsy should be the subject of further research, in order to enable development of evidence-based treatment guidelines for these disorders in epilepsy patients.

PTSD Treatment of African American Adults in Primary Care: The Gap Between Current Practice and Evidence-Based Treatment Guidelines

2011 ◽  
Vol 103 (7) ◽  
pp. 585-593 ◽  
Author(s):  
Ruth Elaine Graves ◽  
John R. Freedy ◽  
Notalelomwan U. Aigbogun ◽  
William B. Lawson ◽  
Thomas A. Mellman ◽  
...  
Keyword(s):  
Primary Care ◽  
African American ◽  
Current Practice ◽  
Treatment Guidelines ◽  
Evidence Based ◽  
Evidence Based Treatment ◽  
Ptsd Treatment ◽  
African American Adults

Development of Evidence-Based Treatment Guidelines for TBI Rehabilitation Care: The Cognitive-Behavioral Treatment Arm

2016 ◽  
Vol 97 (10) ◽  
pp. e100-e101
Author(s):  
Marie Dahdah ◽  
Simon Driver ◽  
Shahid Shafi ◽  
Librada Callender ◽  
Ashley Collinsworth ◽  
...  
Keyword(s):  
Behavioral Treatment ◽  
Treatment Guidelines ◽  
Cognitive Behavioral ◽  
Evidence Based ◽  
Cognitive Behavioral Treatment ◽  
Rehabilitation Care ◽  
Evidence Based Treatment
Sign in / Sign up

Export Citation Format

Share Document